Quick Answer
LISATA THERAPEUTICS, INC. reported R&D Expense of $17.68 million for fiscal year 2021.
LISATA THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2021 | $17.68M | +91.1% |
| 2020 | $9.25M | -14.3% |
| 2019 | $10.80M | +42.2% |
| 2018 | $7.59M | -52.1% |
| 2017 | $15.84M | -5.1% |
| 2016 | $16.70M | -30.1% |
| 2015 | $23.90M | -18.1% |
| 2014 | $29.19M | +72.6% |
| 2013 | $16.92M | +61.9% |
| 2012 | $10.45M | +35.4% |
| 2011 | $7.72M | +0.5% |
| 2010 | $7.68M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2022 | $3.24M | -25.2% | -1.2% |
| March 31, 2022 | $3.28M | -35.4% | -20.5% |
| September 30, 2021 | $4.12M | +36.2% | -4.7% |
| June 30, 2021 | $4.33M | +138.1% | -14.7% |
| March 31, 2021 | $5.08M | +238.6% | +67.6% |
| September 30, 2020 | $3.03M | +0.8% | +66.6% |
| June 30, 2020 | $1.82M | -39.2% | +21.3% |
| March 31, 2020 | $1.50M | -26.4% | -50.1% |
- LISATA THERAPEUTICS, INC. showed an increase of +91.1% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2021 period, LISATA THERAPEUTICS, INC.’s r&d expense has grown by 130.1% (from $7.68 million to $17.68 million).
- The most recent figure is from LISATA THERAPEUTICS, INC.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 22, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: